Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).
Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, Vuillerot C, Baranello G, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Papp G, Gorni K, Kletzl H, Martin C, McIver T, Scalco RS, Staunton H, Yeung WY, Fontoura P, Mercuri E; SUNFISH Working Group.
Oskoui M, et al. Among authors: martin c.
J Neurol. 2023 May;270(5):2547-2549. doi: 10.1007/s00415-023-11658-6.
J Neurol. 2023.
PMID: 37071150
Free PMC article.
No abstract available.